希少疾病用医薬品市場調査

希少疾病用医薬品とは何ですか?

オーファンドラッグは、希少疾患の診断、予防、治療を行います。オーファン疾患とは、まれな疾患または症状のことです。米国では、このような疾患に罹患している人は 20 万人未満です。オーファン疾患は、重篤または致命的であることが多いです。実際、米国政府は 1983 年にオーファンドラッグ法と呼ばれる法律を可決しました。この法律は、安全で効果的なオーファンドラッグの製造を促進します。この法律により、製薬会社はこれらの薬の開発に取り組むことで、一定の経済的利益を得ることができます。

FDA は希少疾患の研究を優先しています。そのため、希少疾患に対する新しい治療法の研究開発を支援しています。もう 1 つの重要な点は、希少疾病用医薬品の指定を受けると、スポンサーは次のようなインセンティブを受けられることです。

• 利用料免除
• 適格臨床試験に対する税額控除
• 承認後、7年間の独占市場権を獲得できる可能性がある

Orphan Drug Market Research: How Leading Sponsors Build Defensible Rare Disease Franchises

Rare disease economics reward sponsors who understand patients before they understand pricing. Orphan drug market research is the discipline that produces that understanding, and it has matured into one of the highest-leverage investments in pharmaceutical strategy.

The economics are unusual. Patient populations are small, sometimes fewer than 5,000 globally, but treatment durations are long and willingness to pay is structural. A well-evidenced launch in Pompe, hereditary angioedema, or transthyretin amyloidosis can sustain a franchise for two decades. The work that separates a successful launch from an underperforming one happens years before approval, in the design of the evidence package and the mapping of the prescriber and payer ecosystem.

Why Orphan Drug Market Research Demands a Different Playbook

Conventional pharmaceutical research assumes accessible HCP panels, established treatment algorithms, and identifiable patient cohorts. Rare disease violates all three assumptions. A condition like Niemann-Pick Type C may have fewer than 100 active prescribers across the United States and Europe combined. Standard quantitative methods collapse at that sample size.

The leading sponsors compensate with depth. They build KOL maps that distinguish between diagnosing physicians, treating physicians, and the small group of investigators who shape the literature. They invest in patient advocacy organization relationships years before Phase III readout. They construct payer value stories around natural history data because randomized comparators rarely exist.

SIS International Research has observed that sponsors who commission structured B2B expert interviews with 25 to 40 specialists across academic medical centers, community practice, and patient advocacy leadership during Phase II consistently produce sharper indication prioritization decisions than those who wait for Phase III data. The interviews surface diagnostic odyssey patterns, off-label competitive activity, and payer evidence gaps that quantitative work cannot detect.

The Evidence Architecture That Drives Market Access

HTA bodies in England (NICE), Germany (G-BA), France (HAS), and Canada (CADTH) each apply distinct frameworks to orphan products. NICE’s highly specialized technologies pathway accepts higher ICERs but demands specific evidence on disease severity and unmet need. Germany’s AMNOG process for orphan drugs grants automatic additional benefit below a revenue threshold, then resets at full dossier review.

The sponsors who clear these gates early treat the payer value story as a research output, not a marketing deliverable. They commission HTA submission evidence work in parallel with Phase II, mapping which endpoints carry weight in each jurisdiction. Real-world evidence from natural history registries, patient-reported outcome instruments validated for the specific condition, and indirect treatment comparisons against standard of care all enter the evidence package before pivotal data lock.

BioMarin’s approach with Voxzogo in achondroplasia and Alnylam’s sequencing of Onpattro, Givlaari, and Amvuttra illustrate the discipline. Each launch reused infrastructure, prescriber relationships, and payer dialogue from the prior program. The franchise compounds.

Diagnostic Odyssey Mapping as Commercial Intelligence

The average rare disease patient sees seven physicians over five years before diagnosis. That diagnostic odyssey is not just a clinical problem. It is the commercial map. Each touchpoint represents a prescriber who may suspect the condition but lacks the genetic testing pathway, the referral network, or the awareness to confirm it.

Patient journey mapping in orphan drug market research traces these touchpoints with the patient and the caregiver, then validates them against claims data and physician interviews. The output identifies the specific specialists, often not the eventual treaters, who gate diagnosis. Companion diagnostic strategy, medical education investment, and field medical deployment all key off this map.

Indication Prioritization When Every Decision Is Capital-Intensive

Most rare disease assets have multiple potential indications. A gene therapy platform may address three conditions; a small molecule may have rationale across five. Sequencing matters because each indication consumes regulatory attention, manufacturing capacity, and commercial bandwidth.

The framework that the strongest sponsors apply weighs four variables: addressable patient population at steady state, regulatory pathway certainty, payer precedent in the indication, and competitive density. Across SIS International Research engagements with rare disease sponsors, indications scoring high on regulatory certainty and payer precedent but moderate on population frequently outperform larger indications with crowded competitive fields, because launch sequencing benefits from clean precedent more than scale.

Source: SIS International Research

Competitive Intelligence in Sparse Pipelines

Rare disease competitive intelligence rewards primary research over database subscriptions. ClinicalTrials.gov captures registered studies, but it misses the academic investigators running natural history work that signals future commercial entry. It misses platform companies, particularly in gene therapy and antisense, that can pivot to a new indication within 18 months.

Structured expert interviews with academic investigators, conference intelligence from podium discussions at WORLDSymposium and ASGCT, and patent landscape analysis on capsid and delivery technology produce a more accurate forward view. Sponsors who commission this work quarterly catch competitive entries two to three years earlier than those relying on commercial databases alone.

Pricing and Access Research Before Phase III

Orphan pricing research starts with payer archetype interviews across at least five major markets. The questions concern budget impact thresholds, managed entry agreement appetite, outcomes-based contract feasibility, and the specific evidence that would move an HTA recommendation from restricted to broad use. Sponsors learn what pricing range is defensible, what evidence closes the gap, and which markets sequence first based on price reference effects.

The mistake to avoid is treating pricing research as a late-stage exercise. Once Phase III protocols lock, the comparator, the endpoint, and the patient subgroup are fixed. Pricing flexibility is fixed with them.

Where the Discipline Is Heading

Three shifts are reshaping orphan drug market research. First, gene therapy and one-time treatments are forcing payer dialogue to address durability evidence and long-term safety registries before launch, not after. Second, AI-enabled diagnostic tools are compressing the diagnostic odyssey in conditions like cardiac amyloidosis and Fabry disease, expanding addressable populations faster than historical models predict. Third, China and Brazil are becoming meaningful rare disease markets, requiring evidence packages adapted to local HTA logic rather than translated from Western dossiers.

Sponsors who treat orphan drug market research as a continuous intelligence function, refreshed at each clinical milestone, build franchises that compound. Those who commission it as a one-time launch input leave value on the table.

SISインターナショナルについて

SISインターナショナル 定量的、定性的、戦略的な調査を提供します。意思決定のためのデータ、ツール、戦略、レポート、洞察を提供します。また、インタビュー、アンケート、フォーカス グループ、その他の市場調査方法やアプローチも実施します。 お問い合わせ 次の市場調査プロジェクトにご利用ください。